IonQ and CCRM Launch Quantum-Biotech Partnership for Advanced Therapeutics

Reuters

Dec 01

IonQ and CCRM Launch <a href="https://laohu8.com/S/QMCO">Quantum</a>-Biotech Partnership for Advanced <a href="https://laohu8.com/S/LENZ">Therapeutics</a>

IonQ Inc., a leading quantum technology company, has announced a strategic partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate the development of advanced therapeutics using hybrid quantum and quantum-AI technologies. As the core technology partner across CCRM's global regenerative medicine network, IonQ will support quantum-biotech initiatives focused on bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation for advanced therapy design and manufacturing. The collaboration includes an investment commitment from IonQ and will launch initial projects in Canada and Sweden in 2026, aiming to revolutionize therapeutic development, biomanufacturing, and healthcare delivery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IONQ Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201706303) on December 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2588278847"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588278847\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588278847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588278847","market":"us","top_or_hot":-1,"title":"IonQ and CCRM Launch Quantum-Biotech Partnership for Advanced Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IonQ and CCRM Launch <a href=\"https://laohu8.com/S/QMCO\">Quantum</a>-Biotech Partnership for Advanced <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IonQ Inc., a leading quantum technology company, has announced a strategic partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate the development of advanced therapeutics using hybrid quantum and quantum-AI technologies. As the core technology partner across CCRM's global regenerative medicine network, IonQ will support quantum-biotech initiatives focused on bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation for advanced therapy design and manufacturing. The collaboration includes an investment commitment from IonQ and will launch initial projects in Canada and Sweden in 2026, aiming to revolutionize therapeutic development, biomanufacturing, and healthcare delivery.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IONQ\">IONQ Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201706303) on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IonQ and CCRM Launch Quantum-Biotech Partnership for Advanced Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIonQ and CCRM Launch Quantum-Biotech Partnership for Advanced Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-01 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IonQ and CCRM Launch <a href=\"https://laohu8.com/S/QMCO\">Quantum</a>-Biotech Partnership for Advanced <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IonQ Inc., a leading quantum technology company, has announced a strategic partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate the development of advanced therapeutics using hybrid quantum and quantum-AI technologies. As the core technology partner across CCRM's global regenerative medicine network, IonQ will support quantum-biotech initiatives focused on bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation for advanced therapy design and manufacturing. The collaboration includes an investment commitment from IonQ and will launch initial projects in Canada and Sweden in 2026, aiming to revolutionize therapeutic development, biomanufacturing, and healthcare delivery.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IONQ\">IONQ Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201706303) on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IONQ","symbol_name":"IONQ Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL8CSCLZ:1","article_id":"2588278847","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588278847","pubTimestamp":1764592244,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IonQ Inc., a leading quantum technology company, has announced a strategic partnership with the Centre for Commercialization of Regenerative Medicine  to accelerate the development of advanced therapeutics using hybrid quantum and quantum-AI technologies. As the core technology partner across CCRM's global regenerative medicine network, IonQ will support quantum-biotech initiatives focused on bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation for advanced therapy design and manufacturing. The collaboration includes an investment commitment from IonQ and will launch initial projects in Canada and Sweden in 2026, aiming to revolutionize therapeutic development, biomanufacturing, and healthcare delivery.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IONQ":"IONQ Inc.","BK4170":"电脑硬件、储存设备及电脑周边","BK4591":"室温超导概念","BK4602":"量子计算概念"},"translate_title":"IonQ和CCRM建立量子生物技术合作伙伴关系以开发先进疗法","themeId":"9d2740edf4f0b98ff0520696a67e8073","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONQ":0.9},"content_text":"IonQ and CCRM Launch Quantum-Biotech Partnership for Advanced Therapeutics\n\n\n        IonQ Inc., a leading quantum technology company, has announced a strategic partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate the development of advanced therapeutics using hybrid quantum and quantum-AI technologies. As the core technology partner across CCRM's global regenerative medicine network, IonQ will support quantum-biotech initiatives focused on bioprocess optimization, disease-modeling workflows, and quantum-enhanced simulation for advanced therapy design and manufacturing. The collaboration includes an investment commitment from IonQ and will launch initial projects in Canada and Sweden in 2026, aiming to revolutionize therapeutic development, biomanufacturing, and healthcare delivery.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IONQ Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201706303) on December 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}